Results

Eli Lilly and Company

12/03/2021 | Press release | Distributed by Public on 12/03/2021 13:53

Lilly's bamlanivimab with etesevimab authorized as the first and only neutralizing antibody therapy for emergency use in COVID-19 patients under the age of 12